Summary of Viatris Conference Call Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Event**: UBS Healthcare Conference - **Date**: November 11, 2025 Key Updates and Financial Performance - Viatris reported a positive momentum in business with an expected operational revenue growth of **2-3%** for 2025, excluding Indor [4][80] - The company is on track to return over **$1 billion** to shareholders, including **$500 million** in share repurchases for the year [4][80] New Product Launches - Anticipated new product revenue is projected to be in the range of **$450 million to $550 million** annually, driven by existing products and upcoming launches [6][4] - Key products contributing to this revenue include: - **Iron sucrose** - **Glucagon** - **Paclitaxel** - Upcoming launches: **Liraglutide**, **Effexor GAD**, **Sotagliflozin** [6][4] Geographic Performance - **North America**: - Experienced competition in generic products, particularly **XULANE LO** [17][22] - Decline primarily attributed to the impact of Indor [19][22] - Strong double-digit growth noted in products like **Breyna** and **Uptravi** [22][22] - **Emerging Markets**: - Strong growth driven by established brand business, particularly in **Turkey**, **Mexico**, and **emerging Asia** [23][23] - Stabilization of lower-margin ARV products has supported growth in the generics business [23][23] - **Japan**: - Facing normal price regulations but focusing on adding innovative assets to stabilize and grow the business [26][26] - Recent acquisition of **Pitolisant** and **Spidea** expected to enhance the portfolio [26][26] - **China**: - Achieved **9% operational growth** driven by a diversified commercial model and strong brand demand [28][28] - Over **10,000 customers** across various channels, with expectations for low to mid-single-digit growth over time [31][31] Pipeline and Future Products - Excitement around **fast-acting meloxicam** as a non-opioid alternative for acute pain management, targeting a launch in the second half of **2026** [34][41] - Anticipated FDA filings for several products, including **Effexor GAD** and **Salatogrel**, with enrollment for Salatogrel on track to complete by the end of **2026** [51][52] Indor Remediation and Strategic Review - Progress on remediation efforts for Indor, with operational readiness for reinspection expected in **2026** [54][54] - An enterprise-wide strategic review initiated to ensure sustainable growth, with details expected in **Q1 2026** [60][60] Capital Allocation Strategy - Viatris maintains a balanced capital allocation strategy, focusing on business development and capital return, with a **50/25/25** framework [71][71] - The company is looking for opportunities to invest in durable, higher-margin innovative assets, particularly in the U.S. market [73][73] Conclusion - Viatris is optimistic about its position going into **2026**, with a focus on executing its strategic priorities, enhancing its product pipeline, and addressing challenges in various markets [80][80]

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $219.3 million, a decrease of 4.7% from Q3 2024. Adjusted EBITDA was $43.6 million, an increase of 1.2% year-over-year, resulting in an adjusted EBITDA margin of 19.9%, up approximately 120 basis points from the prior year [5][11][12]. Business Line Data and Key Metrics Changes - The self-storage segment saw a revenue increase of 3.7%, driven by new construction growth of 5.5%, primarily in the international market, which offset weakness in North America. The R3 sales channel experienced a revenue increase of 0.7% due to door replacement and renovation activities. However, the commercial and other sales channel declined by 20.1%, mainly due to TMC business declines [6][11][12]. - The international segment's revenue increased to $28.3 million, up 32.9% compared to the prior year, driven by new construction growth [11]. Market Data and Key Metrics Changes - The overall market for commercial sheet doors remains soft, but there is growth in rolling steel and the carport and sheds business. The TMC business accounted for approximately 70% of the revenue decline in the quarter due to project timing and weakness in the LTL trucking industry [6][12]. Company Strategy and Development Direction - The company continues to invest in innovation and expand its offerings, including a comprehensive expansion of its metal decking product line and enhancements to the Noke Smart Entry system. The focus remains on capital allocation priorities, including share repurchase and M&A opportunities [9][10][14]. - The self-storage industry is viewed as resilient, with consolidation presenting growth opportunities for the R3 business. The company believes it is well-positioned to deliver long-term shareholder value [10][14]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term fundamentals of the end markets served, supported by a stable backlog and pipeline. They noted that the operating environment remains challenging but emphasized the flexibility of the financial profile and solid cash generation [5][10]. - The company updated its 2025 guidance, expecting revenues in the range of $870 million to $880 million and adjusted EBITDA between $164 million and $170 million, reflecting a slight decrease in EBITDA margins due to geographic and product mix [16]. Other Important Information - The company ended the quarter with $256.2 million in total liquidity, including $178.9 million in cash and equivalents. Total outstanding long-term debt was $554 million, with a net leverage ratio of 2.3 times [14][15]. - S&P upgraded the company's credit rating from B plus to BB minus with a stable outlook, reflecting the resilient business model and consistent cash flow generation [15]. Q&A Session Summary Question: Guidance on revenue and EBIT margin changes - Management indicated that the primary reason for the lower EBIT margin was product and segment mix, with international sales being lower margin compared to North America. Tariffs and input costs were not significant factors [19][20]. Question: Backlogs and customer plans for growth - Management noted that the backlog and pipeline appear stable, with no significant changes from the previous quarter [21]. Question: Weakness in TMC business - The decline in TMC was attributed to project timing and softness in end markets, with expectations for recovery in the fourth quarter and into 2026 [25][26]. Question: Impact of TMC on revenue - The estimated impact from TMC was around $11 million for the quarter, with some projects expected to push into Q4 and 2026 [34]. Question: Raw materials and pricing trends - Management stated that steel prices have remained stable, and they have hedged costs for the upcoming year. They do not anticipate significant changes in pricing trends [47][51]. Question: Cost-saving initiatives - The company has realized about 70% of the expected $10-12 million in cost savings, with further opportunities being explored [57]. Question: Noke system adoption - There is optimism regarding the adoption of the Noke system, particularly among institutional clients, with significant reductions in theft reported [61].

Financial Data and Key Metrics Changes - The company reported underlying replacement cost profit of $2,200,000,000, with a slight increase compared to the prior quarter [19] - Operating cash flow reached $7,800,000,000, which is $1,500,000,000 higher than the previous quarter [19] - The underlying effective tax rate for the third quarter was 39%, with a full-year expectation of around 40% [18] Business Line Data and Key Metrics Changes - Upstream production increased by approximately 3% quarter on quarter, with upstream plant reliability at around 97% [5] - In the Downstream segment, underlying earnings for the first nine months were about 40% higher than the same period in 2024 [3] - The gas and low carbon energy segment's underlying financial result was broadly flat compared to the previous quarter [15] Market Data and Key Metrics Changes - Refining availability was close to 97%, marking the best quarter in twenty years for the current portfolio [5] - The company delivered its highest third quarter on record in customer segments, benefiting from a better margin environment [4] - The oil trading contribution was noted as weak, impacting overall performance [16] Company Strategy and Development Direction - The company is focused on growing the Upstream and enhancing its portfolio while maintaining capital discipline [6][29] - A strategic review of the portfolio is underway to maximize returns and grow shareholder value [29] - The company aims to reduce its realized cash breakeven by $3 per barrel by 2027, translating to approximately $1,500,000,000 of pretax operating cash flow [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational performance and the strength of the resource base, with significant optionality created through exploration success [29] - The company anticipates reported Upstream production to be broadly flat in the fourth quarter, with slight increases expected in oil production and operations [27] - The leadership team is aligned on performance management and accountability, focusing on delivering targets in the short to medium term [31] Other Important Information - The company announced a dividend of $0.08 per ordinary share and a $750,000,000 share buyback for the third quarter [6][24] - Divestment proceeds from noncontrolling interests in Permian and Eagle Ford Midstream assets are expected to exceed $4,000,000,000 in 2025 [28] - The company has made significant progress towards its four primary targets, including accelerating delivery and maximizing cash flow [4] Q&A Session Summary Question: What is the outlook for production in the fourth quarter? - The company expects reported Upstream production to be broadly flat, with slight increases in oil production and operations [27] Question: How is the company addressing cost competitiveness? - The company has delivered around $500,000,000 of incremental structural cost reductions, aiming for a four percentage point improvement in total cash cost to gross margin ratio by year-end [12] Question: What are the plans for shareholder distributions? - The company maintains a policy of a resilient dividend and plans to share excess cash through buybacks, with a target of 30% to 40% of operating cash flow over time [25][26]

Financial Data and Key Metrics Changes - Tangible book value per share plus dividends increased by 17% year over year and 4.5% quarter over quarter [2] - Net attributable profit exceeded €2.5 billion, although it decreased compared to the previous quarter due to higher inflation in Turkey and one-off positive impacts in the second quarter [3] - CET1 capital ratio improved by 8 basis points to 13.42%, providing capacity for increased shareholder remuneration [4] - Cumulative profits for the first nine months reached almost €8 billion, a 4.7% increase year over year [4] Business Line Data and Key Metrics Changes - Core revenues showed strong growth with net interest income and fees increasing by 18% and 15% year over year, respectively [5] - Net interest income grew by 3.2% quarter on quarter in Spain, driven by strong loan growth in profitable segments [19] - In Mexico, net interest income grew by 3.3% quarter on quarter, supported by robust lending activity [21] - Turkey's net attributable profit increased by nearly 50% year over year, driven by higher core revenues [24] Market Data and Key Metrics Changes - Loan growth in Spain accelerated to 7.8% year over year, while Mexico's loan growth was 9.8% year over year [9] - The Mexican peso's appreciation negatively impacted FX hedges this quarter but is expected to benefit in the coming quarters [3] - The cost of risk in Mexico improved, with guidance now expecting it to remain below 340 basis points [24] Company Strategy and Development Direction - The company aims to focus on organic growth and has closed the chapter on the Sabadell transaction, emphasizing future operational focus [45] - A significant share buyback program of nearly €1 billion will commence, alongside a record interim dividend [16] - The company is committed to achieving a cost-to-income ratio of 35% by 2028, with a focus on maintaining operational leverage [68] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about future revenue and profit growth, citing stability in customer spreads and strong loan growth [12] - The company expects interest rates to stabilize, with limited room for further cuts, which will support core revenue growth [11] - The competitive landscape in Mexico is acknowledged, with a focus on leveraging existing strengths to maintain market position [76] Other Important Information - The company acquired a record 8.7 million new customers in the first nine months of 2025, with 66% through digital channels [17] - A record €97 billion was channeled into sustainable business, reflecting the company's commitment to sustainability [17] Q&A Session Summary Question: Loan book growth in Spain and cost of risk in Mexico - Management noted that corporate loan growth in Spain is strong, driven by various sectors, while mortgage growth is limited due to pricing concerns [34][37] - The cost of risk in Mexico is expected to improve, with positive macro adjustments influencing guidance [38][39] Question: Insights on the Sabadell transaction and capital distribution outlook - Management considers the Sabadell transaction a missed opportunity but emphasizes a focus on future growth and shareholder value [45][46] - The company plans to distribute excess capital back to shareholders, targeting a capital level of 11.5% to 12% [46][50] Question: Margins in Spain and Mexico - Management indicated that customer spreads in Spain are stabilizing, with expectations of limited further declines [55][58] - In Mexico, margins are resilient despite falling interest rates, with expectations of stabilization in customer spreads [61][62] Question: Group costs and ambitions for Corporate & Investment Banking (CIB) - Management highlighted a focus on containing costs and achieving a cost-to-income ratio of 35% by 2028 [68] - The CIB business aims for 20% revenue growth, with aspirations to double the business over four years [70][72]

Financial Data and Key Metrics Changes - In Q3 2025, OMA's passenger traffic reached 7.6 million, an 8% year-over-year increase, with seat capacity rising by 11% [3] - Aeronautical revenues increased by 11%, with aeronautical revenue per passenger rising by 3% [4] - Adjusted EBITDA grew by 9% to MXN 2.7 billion, with an adjusted EBITDA margin of 74.8% [5][10] - Consolidated net income for the quarter was MXN 1.5 billion, reflecting a 9.1% increase compared to the same quarter last year [10] - Cash generated from operating activities amounted to MXN 1.9 billion, with a cash position of MXN 4.4 billion at the end of the quarter [11] Business Line Data and Key Metrics Changes - Domestic passenger traffic grew by 7%, primarily driven by Monterrey Airport, contributing significantly to overall growth [3] - International passenger traffic increased by 11%, with notable contributions from routes to San Francisco, Atlanta, and Dallas [4] - Commercial revenues grew by 7%, with commercial revenue per passenger at MXN 60, driven by parking, restaurants, VIP lounges, and retail [4][8] - Industrial services revenues surged by 53%, mainly due to increased leased square meters in the industrial park [9] Market Data and Key Metrics Changes - The occupancy rate for commercial space was 96% at the end of the quarter, indicating strong demand [4] - The overall investment level for the next Master Development Program is expected to remain similar in real terms to the previous program [7] Company Strategy and Development Direction - The company plans to allocate around half of its Master Development Program (MDP) investment to Monterrey, focusing on capacity expansion and commercial opportunities [23] - OMA is exploring international expansion opportunities, although no concrete transactions are currently in place [23] Management Comments on Operating Environment and Future Outlook - Management expects overall traffic growth for the year to be between 7% and 8%, with a forecast of low to mid-single-digit growth for the following year [14] - Cost pressures from AG&E and utility costs are viewed as not permanent, with ongoing efforts to manage costs effectively [19] Other Important Information - Total debt at the end of September was MXN 13.6 billion, with a net debt to adjusted EBITDA ratio of 0.9x, indicating a solid financial position [11] Q&A Session Summary Question: Traffic expectations for Q4 and early thoughts on 2026 - Management anticipates overall traffic growth for the year to be between 7% and 8%, with expectations for next year in the low to mid-single digits [14] Question: Drivers behind the decline in commercial revenue per passenger - The decline is attributed to one-time revenues recorded in the previous year, with expectations for gradual increases in future quarters [17] Question: Outlook on AG&E and utility cost pressures - Cost pressures are not expected to be permanent, with management analyzing alternatives to maintain costs [19] Question: Capital allocation for the next MDP and potential international expansion - Half of the MDP will be allocated to Monterrey, focusing on capacity and commercial opportunities, while international expansion opportunities are being explored [23]

Financial Data and Key Metrics Changes - Total revenues for Q2 2025 were $3,580 million, down approximately 2% year-over-year, but operational revenue growth was approximately 3% when excluding the impact from Indoor [27][28] - Adjusted gross margin for the quarter was 56.6%, consistent with expectations, and operating expenses decreased due to planned cost-saving initiatives [31][32] - Free cash flow generated in the quarter was $167 million, with an adjusted figure of $241 million when excluding transaction-related costs [32] Business Line Data and Key Metrics Changes - In developed markets, brand performance helped offset the Indoor impact, with European business growing approximately 2% and brands portfolio growing approximately 3% [28] - North American business decreased 11% year-over-year, primarily due to Indoor impact and competition, while Emerging Markets saw a 1% increase driven by Turkey and Emerging Asia [29] - Greater China net sales grew 9%, benefiting from proactive patient choice and customer purchasing patterns [30] Market Data and Key Metrics Changes - The company serves approximately one billion patients worldwide each year, with a global supply chain supporting patient access [13] - The U.S. market is expected to see continued growth in generics, although moving additional manufacturing of non-complex generics to the U.S. is deemed difficult in the short term [14][15] - The company anticipates no material impact from proposed U.S. tariffs on its 2025 financial picture, while monitoring developments closely [12][35] Company Strategy and Development Direction - The company is focused on driving strong commercial execution, advancing its late-stage pipeline, and exploring strategic business development opportunities [6][11] - The enterprise-wide strategic review aims to position the company for sustainable growth in 2026 and beyond, with updates expected in the Q3 earnings call [11][54] - The company is committed to returning capital to shareholders through dividends and share buybacks, having returned over $630 million year-to-date [10][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, citing a strong business foundation and a maturing late-stage pipeline [15][16] - The company reiterated its 2025 financial guidance, expecting to be in the top half of the range for revenue and adjusted EPS [15][34] - Management acknowledged the challenges posed by tariffs but does not anticipate a material financial impact in 2025 [48][35] Other Important Information - Five of the six anticipated Phase III readouts have shown positive results, reinforcing the strength of the company's pipeline [7][18] - The company is making progress on remediation efforts at its Indoor facility, with plans to discuss reinspection with the FDA [11][69] - The company has received FDA approval for dorunavir tablets manufactured at its Nashik facility, indicating positive operational progress [12][70] Q&A Session Summary Question: Capital allocation priorities and growth expectations - Management emphasized a balanced approach to capital allocation, focusing on returning capital to shareholders while building a growth portfolio through strategic business development [40][41] Question: Impact of tariffs on revenue from India versus EU - Management stated that it is monitoring the situation closely and does not anticipate a material financial impact from tariffs in 2025 [48] Question: Performance of the China business - The China business saw a 9% operational growth, with expectations for moderate growth in the future, driven by strong brand equity and proactive patient demand [55][56] Question: Contribution from new products in developed markets - Management expects to generate approximately $450 million to $550 million from new product revenue, with a back-half weighting based on approval and launch timing [61][62] Question: Commercial strategy for meloxicam - The company is in the midst of launch planning for meloxicam, focusing on market research and positioning, with expectations for significant opportunity in the acute pain market [66][67]

Financial Data and Key Metrics Changes - Revenue grew 16% in the third fiscal quarter to $5,900,000 compared to $5,100,000 in the prior year [12] - GAAP net income increased from $1,600,000 to $2,000,000, up 27% [14] - Earnings per share basic and diluted was $0.10 per share, compared to $0.08 last year [15] - Total revenue for the fiscal year to date increased 10.3% to $16,800,000 versus $15,300,000 [16] Business Line Data and Key Metrics Changes - Recurring revenue increased 15% to $5,800,000, although the percentage of recurring to total revenue declined from 99% to 98% due to accelerated customer onboarding [13] - Income from operations increased 43% from $1,300,000 to $1,800,000 [14] - The company is experiencing growth across all lines of business, including traceability, compliance, and supply chain [9] Market Data and Key Metrics Changes - The FDA extended the enforcement deadline for compliance by thirty months, allowing more time for smaller distributors and producers to meet requirements [20] - Leading retailers are prioritizing food safety and investing in food traceability, which is driving market adoption [21] Company Strategy and Development Direction - The company aims to grow annual revenue at a double-digit pace between 10% to 20% and profitability even faster [5] - The strategy includes exceptional customer care, flawless execution, and increasing recurring revenue while balancing costs with opportunities [12] - The company is focused on cross-selling initiatives, leveraging a single technology platform to enhance operational efficiencies [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and the ability to convert revenue into cash effectively [28] - The company anticipates returning about 50% of annual cash generation to shareholders through dividends and stock repurchases [28] - Management acknowledged the need for ongoing work to balance opportunities with customer service [28] Other Important Information - The company has over $28,000,000 in cash as of March 31, 2025, net of capital returned to shareholders [15] - The company has redeemed $4,600,000 in preferred stock with approximately $4,200,000 remaining [18] Q&A Session Questions and Answers Question: What is the impact of tariffs on the business? - Management indicated that tariffs introduce uncertainty but have not significantly impacted business operations [32][33] Question: How should changes in the cost structure be viewed? - Management stated that while they will continue to invest in awareness and automation, they do not foresee significant changes in the cost structure [34][36] Question: Can you elaborate on the ability to cross-sell products? - Management highlighted that the single platform allows for significant operating leverage and improved cross-selling capabilities, leading to growth across various business lines [47][48] Question: What are the capital allocation plans regarding stock buybacks and M&A? - Management expressed a preference for building applications in-house rather than acquiring technologies, focusing on domain knowledge and customer acquisition [49][51]

Financial Data and Key Metrics Changes - In 2024, the company reported total revenues of approximately $14.7 billion, reflecting a 2% growth on a divestiture adjusted operational basis compared to 2023 [7][36] - Adjusted EBITDA for 2024 was approximately $4.7 billion, with adjusted gross margins of 58% [7][36] - Free cash flow for 2024 was approximately $2.6 billion, excluding divestiture-related taxes and transaction costs [8][36] - The company anticipates a negative impact of approximately $500 million on total revenues and $385 million on adjusted EBITDA for 2025 due to the remediation efforts at the Indore facility [12][40] Business Line Data and Key Metrics Changes - New product revenues increased to $582 million in 2024, setting a target range of $450 million to $550 million for 2025 [6][17] - The global generics business grew by 2% in 2024, driven by new product launches and complex products [37] Market Data and Key Metrics Changes - North America is expected to decline year over year due to the impact of the Indore facility and expected competition on certain generics [31] - Emerging markets are projected to grow year over year, primarily driven by the expansion of the cardiovascular portfolio in Latin America and key markets such as Turkey and India [32][33] Company Strategy and Development Direction - The company aims to balance capital return and business investment over the next three to five years, with a focus on returning capital to shareholders in 2025 [14][45] - The company is prioritizing new product launches and expects several notable launches in 2025, including complex injectables [12][28] - An enterprise-wide initiative has been launched to review global infrastructure and identify additional cost savings, expected to deliver operational expense savings in 2026 and beyond [15][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive base business growth and execute on the pipeline, despite challenges from the Indore facility [15][39] - The company is committed to quality and is making progress on the remediation plan at the Indore facility, with expectations for completion in a few months [10][40] Other Important Information - The company has engaged independent third-party experts to support remediation efforts at the Indore facility [10] - The company expects to maintain a strong focus on advancing its innovative pipeline, with several Phase III readouts anticipated in 2025 [19][26] Q&A Session Summary Question: Concerns about quality control at other facilities - Management confirmed that only the Indore facility received a warning letter, while other facilities are in compliance [50][52] Question: Timing of Phase III data for Sinerimod and Solatogrel - Management indicated that data is expected in late 2026, but enrollment is progressing well [56] Question: Long-term vision for the company - Management stated that the capital allocation plan remains unchanged, with a focus on returning capital to shareholders while also pursuing business development opportunities [53][54] Question: Impact of Indore facility issues on revenues outside the U.S. - Management explained that remediation efforts could cause supply issues for certain products, affecting revenues in other markets [73] Question: Gross margin expectations and factors affecting them - Management noted that the primary impact on gross margins is from the Indore facility, along with normal price erosion and increased supply costs [68][70]